Selank in stress and withdrawal models: what the rodent studies report

Published August 28, 2026 · Artemis Labs

Selank has been tested in rodent models of alcohol withdrawal, morphine withdrawal and chronic stress, usually with an established drug running alongside it as a comparator. The results are consistent in direction: withdrawal signs were reduced. The detail worth carrying is in the comparison. In the 2022 morphine-withdrawal study, Selank cut the total withdrawal index by 39.6% against diazepam’s 49.3%, and the authors wrote plainly that Selank “was slightly inferior to diazepam” on the measures reported. Our own product description previously described the two as comparable. The source says otherwise, and this page follows the source.

Key findings

• Morphine withdrawal in rats: Selank “reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (р<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased the tactile sensitivity threshold” (PMID 36322304).
• The comparator, verbatim from the same abstract: Selank “was slightly inferior to diazepam … by pharmacological activity (the decrease in total index of morphine withdrawal syndrome by 49.3% and 13-fold increase in sensitivity threshold).”
• Alcohol withdrawal in rats drinking ethanol for 24 weeks: Selank “eliminated anxiety induced by ethanol withdrawal in tests elevated plus maze and social interaction tests and prevented the formation of mechanical allodynia without affecting ethanol consumption” (PMID 24913576).
• In DBA/2 mice, Selank “significantly blocked manifestation of motor sensitization without affecting its formation” (PMID 27878720).

The withdrawal studies

Three studies from the same laboratory make up this lane, and they are unusually consistent in design: outbred or inbred rodents, a single injection of Selank at the dose the authors describe as its anxiolytic dose, an established drug as comparator, and standard behavioral tests.

Alcohol, 2014. Rats drank 10% ethanol as their only fluid for 24 weeks, and the analysis focused on animals consuming more than 5 g/kg a day. After 48 hours of withdrawal, Selank eliminated the anxiety measured in the elevated plus maze and social interaction tests, and prevented mechanical allodynia — heightened sensitivity to touch.

The qualifier in that abstract is the important part: it did this “without affecting ethanol consumption.” The compound changed the withdrawal signs without changing drinking behavior. Those are different outcomes and the study reports the distinction rather than blurring it.

Ethanol sensitisation, 2016. In DBA/2 mice, Selank prevented ethanol-induced hyperlocomotion, as did the opioid blocker naloxone, while a different anxiolytic did not. It blocked the expression of motor sensitisation without affecting its formation — meaning the underlying adaptation still developed; what changed was whether it showed up in behavior.

Morphine, 2022. Naloxone-precipitated withdrawal in morphine-dependent rats, with diazepam as comparator. Selank reduced the total withdrawal index by 39.6% and raised the tactile sensitivity threshold ninefold; diazepam achieved 49.3% and thirteenfold. The authors’ summary sentence is even-handed: “Thus, Selank, like diazepam, weakens the aversive signs of morphine withdrawal in rats with opiate dependence” — while their comparison sentence records Selank as the weaker of the two.

A correction to our own description

Our Selank product record described this study as showing “efficacy comparable to diazepam.” Read against the abstract, that is not accurate. Selank was lower on both reported measures, and the authors chose the phrase “slightly inferior.” The word “comparable” quietly upgrades a second-place result into a tie.

The corrected description is on this page and the underlying record is being fixed. We publish the correction rather than performing it silently for the same reason we publish counter-evidence generally: a page that shows its own errors being caught is more useful than one that has apparently never made any.

Chronic stress and the rest of the body

A separate group studied Wistar rats under chronic restraint stress, and looked where most behavioral studies do not — at the gut.

In one study the colon wall showed signs of atrophy, inflammatory reaction and changed mast cell activity under stress, alongside raised corticosterone. Selank given before stress exposure lowered corticosterone and reduced those changes. In a companion study, chronic stress shifted the balance of gut bacteria — less of the normal population, more opportunistic organisms — and Selank restored it.

Both papers hedge their mechanism carefully, and the hedge is worth quoting because it is the opposite of how such results usually get summarized: the effects “were presumably realized due to multifunctional biological effects of Selank,” and the microbiota restoration happened “presumably via central (neurotropic) and peripheral (immunotropic) mechanisms.” Twice, the authors mark their mechanism as an assumption.

There is also a study in monkeys, published in Russian in 2008, reporting behavioral changes after experimental neurosis. It is the only primate work in the record and it is worth knowing about, though its abstract supports nothing more specific than what its title claims.

What the research does not show

None of this is human research. Every study on this page is in rats, mice or monkeys.

Selank was not shown to outperform its comparator in any of these experiments. In the one study reporting a direct numerical comparison, it came second.

The alcohol study specifically found no effect on how much the animals drank, and the sensitisation study found no effect on how the adaptation formed. Both are cases where the compound changed one measure and left the adjacent one alone, and both are stated in the abstracts.

No study in the record tests whether Selank itself produces dependence or withdrawal. And a US pharmacology review of GABAergic agents describes Selank among “poorly studied Russian drugs” — a fair characterization of an evidence base with no non-Russian replication.

Frequently asked questions

Is Selank as effective as diazepam?

Not in the study that measured both. It reduced the morphine withdrawal index by 39.6% against diazepam’s 49.3%, and the authors called it slightly inferior.

Did Selank reduce drinking in the alcohol study?

No. It reduced withdrawal anxiety and touch sensitivity without affecting ethanol consumption.

Has any of this been tested in people?

Not for withdrawal. The human trials are in anxiety disorders, and they are covered on our human trials page.

Why do the gut studies appear on a stress page?

Because they are stress studies. The model is chronic restraint stress and the measurements happen to be in the colon — part of the same neuroimmune picture as our immune and cytokine research page.

References

1. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bull Exp Biol Med. 2022. PMID 36322304.
2. Kolik LG, Nadorova AV, Kozlovskaya MM. Bull Exp Biol Med. 2014. PMID 24913576. DOI 10.1007/s10517-014-2490-4.
3. Kolik LG, Nadorova AV, Seredenin SB. Bull Exp Biol Med. 2016. PMID 27878720. DOI 10.1007/s10517-016-3544-6.
4. Mukhina AY, Mishina ES, Bobyntsev II, Medvedeva OA, Svishcheva MV, Kalutskii PV, et al. Bull Exp Biol Med. 2020. PMID 32651826. DOI 10.1007/s10517-020-04868-9.
5. Mukhina AY, Medvedeva OA, Svishcheva MV, Shevchenko AV, Efremova NN, Bobyntsev II, et al. Bull Exp Biol Med. 2019. PMID 31236882.
6. Doyno CR, White CM. J Clin Pharmacol. 2021. PMID 34396551.

Methodology: figures and comparator results are quoted verbatim from the published abstracts, retrieved through NCBI E-utilities on August 28, 2026. Doses appear only as part of a described study design.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.